Sequoyitol

Synonyms: 红杉醇; 5-O-Methyl-myo-inositol
Sequoyitol(5-O-Methyl-myo-inositol)是一种具有口服活性的降糖剂与抗氧化剂,可从草本植物中分离,能下调 NF-κB 和 TGF-β1 的表达,降低 ROS 生成量与丙二醛水平,并提升总抗氧化能力,同时增强包括 IR、IRS1 和 Akt 磷酸化在内的胰岛素信号通路,提升血清胰岛素水平,抑制肝脏葡萄糖生成,促进细胞的葡萄糖摄取,拮抗 TNFα 诱导的胰岛素信号通路抑制作用,降低血尿素氮与血清肌酐水平,并可引发 Atrophaneura alcinous 成虫与幼虫化学感受器的电位峰值,同时作为 Atrophaneura alcinous 雌虫的产卵刺激剂,可用于 2 型糖尿病、胰岛素抵抗、高血糖、糖耐量异常及糖尿病肾病的相关研究。
产品编号: MS-L27812 纯度: 98.0% CAS No.: 523-92-2 分子式: C7H14O6 分子量: 194.18
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Sequoyitol(5-O-Methyl-myo-inositol)是一种具有口服活性的降糖剂与抗氧化剂,可从草本植物中分离,能下调 NF-κB 和 TGF-β1 的表达,降低 ROS 生成量与丙二醛水平,并提升总抗氧化能力,同时增强包括 IR、IRS1 和 Akt 磷酸化在内的胰岛素信号通路,提升血清胰岛素水平,抑制肝脏葡萄糖生成,促进细胞的葡萄糖摄取,拮抗 TNFα 诱导的胰岛素信号通路抑制作用,降低血尿素氮与血清肌酐水平,并可引发 Atrophaneura alcinous 成虫与幼虫化学感受器的电位峰值,同时作为 Atrophaneura alcinous 雌虫的产卵刺激剂,可用于 2 型糖尿病、胰岛素抵抗、高血糖、糖耐量异常及糖尿病肾病的相关研究。

生物实验数据

生物活性 Sequoyitol (5-O-Methyl-myo-inositol) is an orally active hypoglycemic and antioxidant agent that can be isolated from herbaceous plants; it downregulates NF-κB and TGF-β1 expression, reduces ROS production and malondialdehyde levels, and enhances total antioxidant capacity, while strengthening insulin signaling pathways including phosphorylation of IR, IRS1, and Akt, elevating serum insulin levels, inhibiting hepatic glucose production, promoting cellular glucose uptake, antagonizing TNFα-induced inhibition of insulin signaling, and lowering blood urea nitrogen and serum creatinine levels; it also elicits electroantennogram responses in chemoreceptors of Atrophaneura alcinous adults and larvae and acts as an oviposition stimulant for Atrophaneura alcinous females, and can be used in research related to type 2 diabetes, insulin resistance, hyperglycemia, impaired glucose tolerance, and diabetic nephropathy.
体外研究
(In Vitro)

Sequoyitol (1-10 μmol·L−1;高糖培养基加入前 1 小时加入) 可保护大鼠系膜细胞免受高糖诱导的活力丧失,其中 10 μmol·L−1 剂量的保护作用更强。
Sequoyitol (1-10 μmol·L−1;高糖培养基加入前 1 小时加入) 可降低高糖诱导的大鼠系膜细胞内 ROS 过度生成,其中 10 μmol·L−1 剂量对 ROS 水平的降低效果更显著。
Sequoyitol (1-10 μmol·L−1) 可降低高糖诱导的大鼠系膜细胞脂质过氧化水平,该效应通过 MDA 水平降低得以体现,其中 10 μmol·L−1 剂量的抑制作用更强。
Sequoyitol (1-10 μmol·L−1) 可提高高糖暴露大鼠系膜细胞的细胞抗氧化能力,其中 10 μmol·L−1 剂量的提升作用更为显著。
Sequoyitol (100 μM; 12 h) 可直接增强 HepG2 细胞中的胰岛素信号通路,包括 IRS1 和 Akt 的磷酸化,并逆转 TNF−α 诱导的胰岛素抵抗。
Sequoyitol (100 μM; 16 h) 可在体外以不依赖胰岛素的方式直接抑制 DB-cAMP 刺激的原代小鼠肝细胞葡萄糖生成,并且与胰岛素联合时可产生相加或协同作用以抑制葡萄糖生成。
Sequoyitol (100 μM; 12 h) 可直接增强 3T3-L1 脂肪细胞中的胰岛素信号通路,包括 IR、IRS1 和 Akt 的磷酸化,并能逆转 TNF-α 诱导的胰岛素抵抗。
Sequoyitol (5-10 mg/mL; 3-6 h) 可呈剂量依赖性地保护 INS-1 胰岛 β 细胞免受 STZ (MS-Q80520) 和 H2O2 诱导的损伤,并增强这些细胞中的胰岛素信号通路。
Sequoyitol (15 mM) 可诱导五龄 Atrophaneura alcinous 幼虫侧锥感器产生单幅度锋电位,引发口上感器产生少量小锋电位,而对其中锥感器无诱发反应。

Western Blot Analysis

Cell Line: human hepatoblastoma HepG2 cells
Concentration: 100 μM
Incubation Time: 12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result: Increased insulin-stimulated phosphorylation of IRS1 by 114% and Akt (pSer473) by 54% compared to control.
Increased insulin-stimulated phosphorylation of IR by 46%, IRS1 by 48%, and Akt (pSer473) by 61% in TNF-α-treated cells compared to TNF-α-only control.

Western Blot Analysis

Cell Line: 3T3-L1 mouse adipocytes
Concentration: 100 μM
Incubation Time: 12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result: Increased insulin-stimulated phosphorylation of IR by 31% and IRS1 by 73% compared to control.
Increased insulin-stimulated phosphorylation of IR by 53%, IRS1 by 69%, and Akt by 74% in TNF-α-treated cells compared to TNF-α-only control.
体内研究
(In Vivo)

Sequoyitol (12.5-50.0 mg/kg;口服;每日;6 周) 可通过降低高血糖、改善肾功能、减轻氧化应激以及下调促纤维化和促炎症介质的表达,改善高脂饮食联合链脲佐菌素诱导的糖尿病大鼠的糖尿病肾病,其中最高剂量的效果最为显著。
Sequoyitol (0.5 nmol/h;皮下注射;持续;23 天) 可通过增强胰岛素信号通路 (包括提高 Akt 磷酸化水平、降低 IRS1 Ser307 磷酸化水平) 改善 ob/ob 小鼠的高血糖、高胰岛素血症、胰岛素抵抗及葡萄糖耐受不良症状。
Sequoyitol (40 mg/kg;口服;每日 2 次;最长 31 天) 可通过增强胰岛素敏感性改善雌雄两种性别 ob/ob 小鼠的高血糖和葡萄糖耐受不良症状,且不会改变小鼠的体重或血浆胰岛素水平。
Sequoyitol (70-100 mg·kg-1·day-1;通过饮用水口服;连续) 可降低 STZ (MS-Q80520) 诱导的胰岛素缺乏型 C57BL/6 小鼠的高血糖水平,改善其葡萄糖耐量异常,并提升血浆胰岛素水平。

Animal Model: Sprague-Dawley (male, 6-8 weeks old, 180-220 g, induced by 4-week high-fat diet + intraperitoneal streptozotocin injection)
Dosage: 12.5 mg/kg; 25.0 mg/kg; 50.0 mg/kg
Administration: p.o.; daily; 6 weeks
Result: Significantly decreased fasting blood glucose levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant reductions (# P < 0.05, ## P < 0.01).
Significantly increased plasma insulin levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant elevations (# P < 0.05, ## P < 0.01).
Significantly decreased serum creatinine (SCr) and blood urea nitrogen (BUN) levels compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reduction in SCr (## P < 0.01) and all doses producing statistically significant reductions in BUN (# P < 0.05, ## P < 0.01).
Improved renal histopathology, reducing glomerular hypertrophy, mesangial cell proliferation, and extracellular matrix accumulation compared to the diabetic model group.
Significantly decreased renal collagen IV mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal p22phox and p47phox mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).
Significantly decreased renal malondialdehyde (MDA) levels and increased total antioxidative capacity (T-AOC) compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant changes (## P < 0.01).
Significantly decreased renal NF-κB mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal TGF-β1 mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).
Animal Model: ob/ob (male and female, 8-9 wk old, genetic obesity/insulin resistance model)
Dosage: 40 mg/kg
Administration: p.o.; twice daily; up to 31 days
Result: Did not alter body weight in males or females.
Reduced fasting blood glucose significantly in males (P=0.014) and reduced in females (P=0.08) compared to controls.
Lowered blood glucose levels significantly at multiple time points post-glucose injection during GTT in both sexes.
Maintained plasma insulin levels similar to control groups.
Lowered blood glucose levels significantly at 15, 30, and 60 minutes post-insulin injection during ITT in both males and females.
Animal Model: C57BL/6 (male, 9 wk old, insulin deficiency model induced by streptozotocin injection)
Dosage: 70-100 mg·kg-1·day-1
Administration: p.o.
Result: Did not alter body weight.
Reduced random-fed blood glucose significantly at days 22 and 31 post-treatment, with a 26% reduction at day 31 compared to controls.
Increased plasma insulin levels by 155% compared to controls.
Lowered blood glucose levels significantly at 60 and 120 minutes post-glucose injection during GTT.
Reduced AUC during GTT significantly.
性状 固体
颜色 White to off-white

化学信息

分子量 194.18
分子式 C7H14O6
CAS No. 523-92-2
别名 红杉醇; 5-O-Methyl-myo-inositol

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (514.99 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM5.1499 mL25.7493 mL51.4986 mL128.7465 mL
5 mM1.0300 mL5.1499 mL10.2997 mL25.7493 mL
10 mM0.5150 mL2.5749 mL5.1499 mL12.8747 mL
15 mM0.3433 mL1.7166 mL3.4332 mL8.5831 mL
20 mM0.2575 mL1.2875 mL2.5749 mL6.4373 mL
25 mM0.2060 mL1.0300 mL2.0599 mL5.1499 mL
30 mM0.1717 mL0.8583 mL1.7166 mL4.2916 mL
40 mM0.1287 mL0.6437 mL1.2875 mL3.2187 mL
50 mM0.1030 mL0.5150 mL1.0300 mL2.5749 mL
60 mM0.0858 mL0.4292 mL0.8583 mL2.1458 mL
80 mM0.0644 mL0.3219 mL0.6437 mL1.6093 mL
100 mM0.0515 mL0.2575 mL0.5150 mL1.2875 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础